JPMorgan Chase & Co. increased its position in Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report) by 131.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 228,652 shares of the company's stock after buying an additional 129,854 shares during the quarter. JPMorgan Chase & Co. owned 0.59% of Viemed Healthcare worth $1,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also added to or reduced their stakes in the company. EntryPoint Capital LLC bought a new stake in shares of Viemed Healthcare during the fourth quarter worth about $92,000. Segall Bryant & Hamill LLC purchased a new position in Viemed Healthcare during the 4th quarter worth $297,000. Prudential Financial Inc. bought a new stake in shares of Viemed Healthcare in the 4th quarter worth $93,000. LPL Financial LLC raised its holdings in shares of Viemed Healthcare by 1.6% in the fourth quarter. LPL Financial LLC now owns 194,690 shares of the company's stock valued at $1,561,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Globeflex Capital L P bought a new position in shares of Viemed Healthcare during the fourth quarter valued at about $307,000. Institutional investors own 74.24% of the company's stock.
Viemed Healthcare Stock Up 1.7 %
VMD stock traded up $0.12 during trading on Wednesday, reaching $7.07. The stock had a trading volume of 142,399 shares, compared to its average volume of 139,150. The company has a quick ratio of 1.19, a current ratio of 1.31 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $279.43 million, a price-to-earnings ratio of 26.19 and a beta of 1.64. Viemed Healthcare, Inc. has a one year low of $6.21 and a one year high of $9.81. The company's 50 day moving average is $7.19 and its two-hundred day moving average is $8.03.
Viemed Healthcare Profile
(
Free Report)
Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
Further Reading

Before you consider Viemed Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viemed Healthcare wasn't on the list.
While Viemed Healthcare currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.